Inventor · disambiguated record
Crystal Mackall
Also filed as: MACKALL CRYSTAL · MACKALL CRYSTAL L
21 granted patents·26 pending applications·88 citations·filing 2006–2024
93Inventor score
Files withUNIV LELAND STANFORD JUNIOR27US HEALTH12THE UNITED STATES OF AMERICA AS PRESENTED BY THE SEC DEP OF HEALTH AND HUMAN SERVICES2BERZOFSKY JAY A1CHILDRENS HOSPITAL PHILADELPHIA1
Top patents by PatentIndex Score
47 records- 0196US9868774B2Anti-CD22 chimeric antigen receptorsUS HEALTH·Filed 2012·Granted Jan 16, 2018·36 cites·20 claims
- 0296US9790282B2Anti-CD276 polypeptides, proteins, and chimeric antigen receptorsUS HEALTH·Filed 2014·Granted Oct 17, 2017·28 cites·29 claims
- 0392US10703816B2M971 chimeric antigen receptorsUS HEALTH·Filed 2018·Granted Jul 7, 2020·3 cites·18 claims
- 0488US10072078B2M971 chimeric antigen receptorsUS HEALTH·Filed 2013·Granted Sep 11, 2018·7 cites·18 claims
- 0587US11980640B2Bicistronic chimeric antigen receptors and their usesUS HEALTH·Filed 2018·Granted May 14, 2024·3 cites·20 claims
- 0685US2024084008A1M971 chimeric antigen receptorsUS HEALTH·Filed 2023·Application pending·0 cites
- 0785US2024084007A1M971 chimeric antigen receptorsUS HEALTH·Filed 2023·Application pending·0 cites
- 0884US10738116B2Dual specific anti-CD22-anti-CD19 chimeric antigen receptorsTHE UNITED STATES OF AMERICA AS REPRESENTED BY THE SECRETARY DEPT OF HEALTH AND HUMAN SERVICES·Filed 2016·Granted Aug 11, 2020·3 cites·24 claims
- 0981US11400117B2Compositions and methods for inhibiting T cell exhaustionUNIV LELAND STANFORD JUNIOR·Filed 2018·Granted Aug 2, 2022·2 cites·12 claims
- 1079US2023110875A1Anti-cd276 polypeptides, proteins, and chimeric antigen receptorsTHE UNITED STATES OF AMERICA AS PRESENTED BY THE SEC DEP OF HEALTH·Filed 2022·Application pending·0 cites
- 1178US2025034244A1Bicistronic chimeric antigen receptors and their usesUS HEALTH·Filed 2024·Application pending·0 cites
- 1277US10604583B2Anti-CD276 polypeptides, proteins, and chimeric antigen receptorsTHE UNITED STATES OF AMERICA AS PRESENTED BY THE SEC DEP OF HEALTH AND HUMAN SERVICES·Filed 2017·Granted Mar 31, 2020·1 cites·22 claims
- 1377US7867977B2Immunogenic peptides and methods of use for treating and preventing cancerUS HEALTH·Filed 2006·Granted Jan 11, 2011·2 cites·17 claims
- 1476US12454562B2Regulatable cell surface receptors and related compositions and methodsUNIV LELAND STANFORD JUNIOR·Filed 2019·Granted Oct 28, 2025·1 cites·11 claims
- 1573US11807682B2M971 chimeric antigen receptorsUS HEALTH·Filed 2020·Granted Nov 7, 2023·0 cites·26 claims
- 1671US12454579B2Compositions and methods for inhibiting T cell exhaustionUNIV LELAND STANFORD JUNIOR·Filed 2022·Granted Oct 28, 2025·0 cites·10 claims
- 1770US10562952B2Anti-CD276 chimeric antigen receptorsUS HEALTH·Filed 2016·Granted Feb 18, 2020·2 cites·8 claims
- 1870US2024309324A1Compositions and methods of expansion of t cell populationsUNIV LELAND STANFORD JUNIOR·Filed 2024·Application pending·0 cites
- 1969US11512138B2Anti-CD276 polypeptides, proteins, and chimeric antigen receptorsTHE UNITED STATES OF AMERICA AS PRESENTED BY THE SEC DEP OF HEALTH AND HUMAN SERVICES·Filed 2020·Granted Nov 29, 2022·0 cites·20 claims
- 2066US2024293461A1Methods of Treating T Cell Exhaustion by Inhibiting or Modulating T Cell Receptor SignalingUNIV LELAND STANFORD JUNIOR·Filed 2024·Application pending·0 cites
- 2163US12024716B2Compositions and methods of expansion of T cell populationsUNIV LELAND STANFORD JUNIOR·Filed 2019·Granted Jul 2, 2024·0 cites·19 claims
- 2263US9206245B2Immunogenic peptides and methods of use for treating and preventing cancerUS HEALTH·Filed 2013·Granted Dec 8, 2015·0 cites·11 claims
- 2363US2025249100A1Compositions and methods for preventing t cell exhaustionUNIV LELAND STANFORD JUNIOR·Filed 2023·Application pending·0 cites
- 2462US2025134998A1T cells with cell-surface expression of adenosine deaminase and uses thereofUNIV LELAND STANFORD JUNIOR·Filed 2022·Application pending·0 cites
- 2559US2025320270A1Polypeptide constructs with novel binding affinity and uses thereofUNIV LELAND STANFORD JUNIOR·Filed 2022·Application pending·0 cites
- 2658US11433098B2Compositions and methods for treatment of cancers harboring an H3K27M mutationUNIV LELAND STANFORD JUNIOR·Filed 2018·Granted Sep 6, 2022·0 cites·18 claims
- 2757US11938153B2Methods of treating T cell exhaustion by inhibiting or modulating T cell receptor signalingUNIV LELAND STANFORD JUNIOR·Filed 2018·Granted Mar 26, 2024·0 cites·14 claims
- 2856US12473344B2Chimeric antigen receptor polypeptides and methods of using sameUNIV LELAND STANFORD JUNIOR·Filed 2019·Granted Nov 18, 2025·0 cites·10 claims
- 2956US2024390497A1Compositions of chimeric antigen receptor (car) signaling molecules and uses thereofUNIV LELAND STANFORD JUNIOR·Filed 2022·Application pending·0 cites
- 3056US2023383361A1Methods to predict outcomes to chimeric antigen receptor t-cells in lymphoma from cell-free dna and genetic mutationsUNIV LELAND STANFORD JUNIOR·Filed 2021·Application pending·0 cites
- 3156US2023248824A1Immune cells with increased glycolytic fluxTHE BOARD OF TRUTEES OF THE LELAND STANFORD JUNIOR UNIV·Filed 2021·Application pending·0 cites
- 3256US2023398061A1Injectable hydrogels for adoptive cell therapyUNIV LELAND STANFORD JUNIOR·Filed 2021·Application pending·0 cites
- 3354US2016280798A1Alk antibodies, conjugates, and chimeric antigen receptors, and their useTHE US SECRETRY DEPT OF HEALTH & HUMAN SERVICE·Filed 2014·Application pending·0 cites
- 3453US2024207314A1Methods to improve t cell efficacy and safety by modulating mediators of phagocytosisUNIV LELAND STANFORD JUNIOR·Filed 2022·Application pending·0 cites
- 3552US8614304B2Immunogenic peptides and methods of use for treating and preventing cancerBERZOFSKY JAY A·Filed 2010·Granted Dec 24, 2013·0 cites·20 claims
- 3652US2023348559A1Novel t-cell specificities and uses thereofUNIV LELAND STANFORD JUNIOR·Filed 2021·Application pending·0 cites
- 3752US2024139320A1Chimeric antigen receptor (car) signaling molecules for controlled and specific car t cell activityUNIV LELAND STANFORD JUNIOR·Filed 2022·Application pending·0 cites
- 3851US2025195650A1Methods and compositions for enhancing efficacy of therapeutic immune cellsUNIV LELAND STANFORD JUNIOR·Filed 2021·Application pending·0 cites
- 3951US2025281532A1Methods for diagnosing or treating health conditions or optimizing therapeutic efficacy of car-t cells therapiesUNIV LELAND STANFORD JUNIOR·Filed 2021·Application pending·0 cites
- 4050US2024377394A1Cell Selection Methods and Related CompositionsUNIV LELAND STANFORD JUNIOR·Filed 2022·Application pending·0 cites
- 4148US2022315665A1Chimeric antigen receptors targeting glypican-2UNIV LELAND STANFORD JUNIOR·Filed 2020·Application pending·0 cites
- 4248US2021393628A1Compositions and methods for modulating t cell exhaustionUNIV LELAND STANFORD JUNIOR·Filed 2019·Application pending·0 cites
- 4347US12371469B2Therapeutic antigen binding proteins specific for CD93 and methods of use thereofUNIV LELAND STANFORD JUNIOR·Filed 2020·Granted Jul 29, 2025·0 cites·20 claims
- 4447US2022257653A1Chimeric antigen receptors containing glypican 2 binding domainsCHILDRENS HOSPITAL PHILADELPHIA·Filed 2020·Application pending·0 cites
- 4546US2024082399A1Recombinant polypeptides for regulatable cellular localizationUNIV LELAND STANFORD JUNIOR·Filed 2020·Application pending·0 cites
- 4645US2023183312A1Chimeric antigen receptors with cd2 activationUNIV LELAND STANFORD JUNIOR·Filed 2021·Application pending·0 cites
- 4745US2022218751A1Enhancement of polypeptides and chimeric antigen receptors via hinge domainsUNIV LELAND STANFORD JUNIOR·Filed 2020·Application pending·0 cites
Join the waitlist — get patent alerts
Get an alert when Crystal Mackall files or is granted a new patent.
We store only your email — no account needed. See our privacy policy.
Identity basis: PatentsView inventor disambiguation (2025Q4-odp release). How scoring works →